MDT

88.31

+0.48%↑

VEEV

277.57

-2.02%↓

A

120.68

+1.36%↑

WBA

11.51

+0.09%↑

HQY

102.85

+1.23%↑

MDT

88.31

+0.48%↑

VEEV

277.57

-2.02%↓

A

120.68

+1.36%↑

WBA

11.51

+0.09%↑

HQY

102.85

+1.23%↑

MDT

88.31

+0.48%↑

VEEV

277.57

-2.02%↓

A

120.68

+1.36%↑

WBA

11.51

+0.09%↑

HQY

102.85

+1.23%↑

MDT

88.31

+0.48%↑

VEEV

277.57

-2.02%↓

A

120.68

+1.36%↑

WBA

11.51

+0.09%↑

HQY

102.85

+1.23%↑

MDT

88.31

+0.48%↑

VEEV

277.57

-2.02%↓

A

120.68

+1.36%↑

WBA

11.51

+0.09%↑

HQY

102.85

+1.23%↑

Search

Erasca Inc

Avatud

1.44 0.7

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.4

Max

1.47

Põhinäitajad

By Trading Economics

Sissetulek

1.3M

-31M

Aktsiakasum

-0.11

Töötajad

103

EBITDA

-750K

-36M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+200.69% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

8. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-34M

360M

Eelmine avamishind

0.74

Eelmine sulgemishind

1.44

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Erasca Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. juuli 2025, 15:29 UTC

Suurimad hinnamuutused turgudel

Mustang Bio Shares Jump After Orphan Drug Designation for Cancer Treatment

7. juuli 2025, 23:44 UTC

Market Talk

Nikkei May Fall on U.S. Tariff Concerns -- Market Talk

7. juuli 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. juuli 2025, 23:41 UTC

Market Talk

Gold Edges Lower Amid Hopes for Possible Trade Agreements -- Market Talk

7. juuli 2025, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

7. juuli 2025, 23:19 UTC

Market Talk

AML3D Bull Sees Navy Letter Lowering Risks -- Market Talk

7. juuli 2025, 22:20 UTC

Market Talk

Global Equities Roundup: Market Talk

7. juuli 2025, 22:20 UTC

Market Talk

AT&T's Fiber Strategy Positions Stock to Outperform -- Market Talk

7. juuli 2025, 21:34 UTC

Omandamised, ülevõtmised, äriostud

BlackRock's Latest Acquisition Is a Commercial Real Estate Bet -- Barrons.com

7. juuli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. juuli 2025, 20:45 UTC

Omandamised, ülevõtmised, äriostud

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7. juuli 2025, 20:16 UTC

Market Talk

Canada Bonds Set to Benefit From Rotation Away U.S. Assets -- Market Talk

7. juuli 2025, 19:37 UTC

Market Talk

U.S. Natural Gas Futures Hold Their Ground -- Market Talk

7. juuli 2025, 19:12 UTC

Market Talk

Oil Futures Shrug Off Bigger OPEC+ Output Increase -- Market Talk

7. juuli 2025, 18:33 UTC

Market Talk

Gold Flat as Investors Assess Market Direction -- Market Talk

7. juuli 2025, 18:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. juuli 2025, 16:53 UTC

Tulu

Freight Stocks Have a Tariff Overhang. Morgan Stanley Says It Could Be Worse. -- Barrons.com

7. juuli 2025, 16:30 UTC

Market Talk

Higher Prices Limit Power Sector's Natural Gas Use -- Market Talk

7. juuli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. juuli 2025, 16:05 UTC

Omandamised, ülevõtmised, äriostud

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7. juuli 2025, 15:41 UTC

Market Talk

Gold Futures Fall as Stronger U.S. Dollar Undermines Safe-Haven Demand -- Market Talk

7. juuli 2025, 15:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7. juuli 2025, 15:40 UTC

Market Talk

Base Metal Prices Tick Lower on U.S. Dollar Strength -- Market Talk

7. juuli 2025, 15:30 UTC

Market Talk

Physical Oil Market Stable But Structural Weakness Looms -- Market Talk

7. juuli 2025, 15:18 UTC

Market Talk

BNP Cuts Brent Forecast on U.S. Shale, Iran Supply Resilience -- Market Talk

7. juuli 2025, 15:14 UTC

Omandamised, ülevõtmised, äriostud

MicroStrategy Goes a Week Without Buying Bitcoin. Saylor Has Advice for Crypto Traders. -- Barrons.com

7. juuli 2025, 15:00 UTC

Omandamised, ülevõtmised, äriostud

GSK Completes Acquisition of Efimosfermin

7. juuli 2025, 14:52 UTC

Market Talk

Dollar Faces Downward Pressures Stemming from Tariffs -- Market Talk

7. juuli 2025, 14:51 UTC

Market Talk

Bullish Factors Lift Oil Despite Downward Pressure -- Market Talk

7. juuli 2025, 14:45 UTC

Market Talk

Saudi Arabia Not Seeking to Take Oil Market Share -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Erasca Inc Prognoos

Hinnasiht

By TipRanks

200.69% tõus

12 kuu keskmine prognoos

Keskmine 4.33 USD  200.69%

Kõrge 6 USD

Madal 3 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Erasca Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.39 / 1.44Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Very Strong Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.